Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | TSPO | P30536 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KDM6B | O15054 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742273 | 0.87 | CTNNB1 (0.65) | KDM4CALDH1A1MAPK1HSD17B10GPBAR1 | |
| SCHEMBL238351 | 0.86 | KDM4C (0.59) | KDM4CALDH1A1MAPK1HSD17B10CTNNB1 | |
| SCHEMBL10237798 | 0.85 | GPBAR1 (0.51) | KDM4CALDH1A1MAPK1HSD17B10GPBAR1 | |
| SCHEMBL874453 | 0.85 | PTGS1 (0.48) | KDM4CALDH1A1MAPK1HSD17B10GPBAR1 | |
| SCHEMBL4042446 | 0.84 | TDP1 (0.55) | KDM4CALDH1A1MAPK1HSD17B10GPBAR1 | |
| SCHEMBL851190 | 0.82 | CA12 (0.58) | KDM4CMAPK1GPBAR1MEN1KMT2A | |
| SCHEMBL4939073 | 0.82 | ALDH1A1 (0.71) | ALDH1A1MAPK1HSD17B10TSHRMEN1 | |
| SCHEMBL2506700 | 0.81 | CYP1A2 (0.52) | KDM4CALDH1A1MAPK1HSD17B10GPBAR1 | |
| SCHEMBL7995846 | 0.79 | ALDH1A1 (0.45) | KDM4CALDH1A1MAPK1HSD17B10GPBAR1 | |
| SCHEMBL20243459 | 0.78 | TDP1 (0.48) | KDM4CALDH1A1TSHRKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510338-A | Natural naphthoquinone derivative and preparation method and application thereof | 贵州大学 | 2024-02-06 | — | — | CN | claimed |
| CN-104066737-B | As P2X7Heterocyclic amide derivatives of receptor antagonists | 埃科特莱茵药品有限公司 | 2016-06-08 | — | — | CN | claimed |
| CN-104066737-A | As P2X7Heterocyclic amide derivatives of receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2014-09-24 | — | — | CN | claimed |
| CN-117510338-A | Natural naphthoquinone derivative and preparation method and application thereof | 贵州大学 | 2024-02-06 | — | — | CN | disclosed |
| US-20200360355-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2020-11-19 | — | — | US | disclosed |
| US-10772876-B2 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch | Xeniopro GmbH (DE) | 2020-09-15 | — | — | US | disclosed |
| US-20190083476-A1 | ENHANCERS OF NOTCH SIGNALING AND THE USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2019-03-21 | — | — | US | disclosed |
| EP-3429576-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017158190-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Ecole polytechnique fédérale de Lausanne (EPFL) (CH) | 2017-09-21 | — | — | WO | disclosed |
| CN-104066737-B | As P2X7Heterocyclic amide derivatives of receptor antagonists | 埃科特莱茵药品有限公司 | 2016-06-08 | — | — | CN | disclosed |
| CN-104066737-A | As P2X7Heterocyclic amide derivatives of receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2014-09-24 | — | — | CN | disclosed |
| US-8034940-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| EP-1986645-A1 | GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007089512-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-5707933-A | PLANT GROWTH REGULATORS AND ANTIGROWTH AGENTS | AMERICAN CYANAMID COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0053011-B1 | NEW HERBICIDAL NICOTINAMIDE DERIVATIVES | MAY & BAKER LIMITED (GB) | 1985-04-03 | — | — | EP | disclosed |
| EP-0053011-A1 | New herbicidal nicotinamide derivatives | MAY & BAKER LIMITED (GB) | 1982-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772876-B2 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch | NOTCH1, DNER, NOTCH4 | KDM4C 2499/4885ALDH1A1 4100/4885MAPK1 1030/4885 |
| US-20200360355-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | NOTCH1, DNER, NOTCH4 | KDM4C 2437/4885ALDH1A1 4068/4885MAPK1 1119/4885 |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFRKB, NFKB1 | KDM4C 3470/4885ALDH1A1 3409/4885MAPK1 225/4885 |
| US-20190083476-A1 | ENHANCERS OF NOTCH SIGNALING AND THE USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | NOTCH1, DNER, NOTCH4 | KDM4C 2499/4885ALDH1A1 4100/4885MAPK1 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.